Association Between Diabetes Technology Use and Glycemic Outcomes in Adults With Type 1 Diabetes Over a Decade
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate change in mean clinic HbA1c from 2014 to 2021 with diabetes technology use in adults with type 1 diabetes. RESEARCH DESIGN AND METHODS: In this single-center study, we analyzed diabetes technology use and mean clinic HbA1c among unique adults (age ≥18 years) with type 1 diabetes (last visit of the year per patient) between 1 January 2014 and 31 December 2021 from the electronic medical record. Diabetes technology use was defined as the use of continuous glucose monitors (CGMs) without an automated insulin delivery (AID) system or an AID system. Diabetes technology use and HbA1c over time were analyzed using mixed models adjusted for age, sex, and visit year. RESULTS: A total of 15,903 clinic visits over 8 years (mean 1,988 patients per year, 4,174 unique patients, 52.7% female, 80.0% Non-Hispanic White) showed significant increases in CGM and AID use (P < 0.001 for both), resulting in an increase of diabetes technology use from 26.9% in 2014 to 82.7% in 2021. These increases were associated with a lower mean clinic HbA1c (7.7–7.5%, P < 0.001) and a higher percentage of adults achieving an HbA1c <7.0% (32.3–41.7%, P < 0.001) from 2014 to 2021. The HbA1c difference between technology users and nonusers increased over time from 0.36% (95% CI 0.26–0.47%, P < 0.001) in 2014 to 0.93% (95% CI 0.80–1.06%, P < 0.001) in 2021. CONCLUSIONS: Adopting diabetes technology in adults with type 1 diabetes decreased HbA1c and increased the number of people achieving an HbA1c <7.0%, supporting the current international recommendation to offer AID systems to most individuals with type 1 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, use of diabetes technology overall improves A1C and increases the number of people achieving an A1C <7% (14).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [14]
Citations
Cites
State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Bulletin of the World Health Organization · doi:10.2471/blt.07.045120 · Cited by 1,632
Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Lind, M., Polonsky, W., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., Schwarz, E., Ólafsdóttir, A. F., Frid, A., Wedel, H., et al. (2017) · JAMA · doi:10.1001/jama.2016.19976 · Cited by 705
6. Glycemic Targets: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s006 · Cited by 684
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Heinemann, L., Freckmann, G., Ehrmann, D., Faber-Heinemann, G., Guerra, S., Waldenmaier, D., & Hermanns, N. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30297-6 · Cited by 522
Phillip, M., Nimri, R., Bergenstal, R. M., Barnard-Kelly, K., Danne, T., Hovorka, R., Kovatchev, B. P., Messer, L. H., Parkin, C. G., Ambler-Osborn, L., et al. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac022 · Cited by 443
Self-citationAleppo, G., Ruedy, K. J., Riddlesworth, T. D., Kruger, D. F., Peters, A. L., Hirsch, I., Bergenstal, R. M., Toschi, E., Ahmann, A. J., Shah, V. N., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2482 · Cited by 329
Self-citation
Cited by
7. Diabetes Technology: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s007 · Cited by 348
7. Diabetes Technology: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s007 · Cited by 280
Semaglutide in Adults with Type 1 Diabetes and Obesity
Shah, V. N., Akturk, H. K., Kruger, D., Ahmann, A., Bhargava, A., Bakoyannis, G., Pyle, L., & Snell-Bergeon, J. K. (2025) · NEJM Evidence · doi:10.1056/evidoa2500173 · Cited by 62
Self-citationEffectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes
Snell-Bergeon, J. K., Kaur, G., Renner, D., Akturk, H. K., Beatson, C., & Garg, S. K. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0328 · Cited by 40
“32 Most of the patients in this study did not reach the 1 or 2 mg dose of semaglutide or the 15 mg dose of tirzepatide as recommended for patients with T2D.”
Self-citationShah, V. N., Peters, A. L., Umpierrez, G. E., Sherr, J. L., Akturk, H. K., Aleppo, G., Bally, L., Cengiz, E., Cinar, A., Dungan, K., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241291512 · Cited by 36
“3,103,104 The difficulty with attaining more targeted glycemia is multifactorial; however, two factors are likely most instrumental with this struggle.”
Self-citationPerioperative Care of Patients Using Wearable Diabetes Devices
Cruz, P., McKee, A. M., Chiang, H.-H., McGill, J. B., Hirsch, I. B., Ringenberg, K. J., & Wildes, T. S. (2024) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000007115 · Cited by 38
Jia, Y., Long, D., Yang, Y., Wang, Q., Wu, Q., & Zhang, Q. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111757 · Cited by 36
Aktürk, H. K., Battelino, T., Castañeda, J., Arrieta, A., van den Heuvel, T. R. A., & Cohen, O. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0432 · Cited by 27
Karakus, K. E., Klein, M. P., Aktürk, H. K., & Shah, V. N. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01592-9 · Cited by 25
“The automated insulin delivery system (AID) is the standard of care in managing T1D [5] and has been shown to improve glycemic outcomes compared to multiple daily injections (MDI) and insulin pump (continuous subcutaneous insulin infusion, CSII) use alone [6, 7].”
BackgroundSelf-citationAkturk, H. K., American Diabetes Association Diabetes Technology Interest Group, Aloi, J., Shah, V. N., Akturk, H. K., McKee, A. M., Ekhlaspour, L., Kim, S., & Everett, E. (2024) · Clinical Diabetes · doi:10.2337/cd23-0080 · Cited by 16
Self-citationThe future is here: an overview of technology in diabetes
Mallik, R., Kar, P. S., Mulder, H., & Krook, A. (2024) · Diabetologia · doi:10.1007/s00125-024-06235-z · Cited by 23
Ghosh, N., & Verma, S. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2422005 · Cited by 19
“In the linear mixed model adjusted for age, sex, and visit year, HbA 1c decreased over time ( p 0.001), whereas the use of diabetes technology with a 0.53% reduction in HbA 1c (95% CI 0.49–0.58%, p 0.001) 22,23 .”
InfluentialWang, Y., Lu, J., Wang, M., Ni, J., Yu, J., Wang, S., Wu, L., Lu, W., Zhu, W., Guo, J., et al. (2024) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2024.101067 · Cited by 21
“Despite broad-based evidence supporting the use of CGM to improve glucose outcomes in outpatients, 21,22 the technology remains largely investigational in the hospital setting.”
Kim, J. Y., Ilham, S., Alshannaq, H. A., Pollock, R. F., Ahmed, W., Norman, G. J., Jin, S., & Kim, J. H. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2405293 · Cited by 12
“Based on evidence from other longitudinal studies, the reduction in HbA1c was conservatively assumed to be sustained for three years (i.e. two additional years after the first year) in the rt-CGM arm 20–22 .”
Simonson, G. D., Criego, A. B., Battelino, T., Carlson, A. L., Choudhary, P., Franc, S., Gershenoff, D. C., Grunberger, G., Hirsch, I. B., Isaacs, D. M., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0107 · Cited by 11
Stephen, D. A., Nordin, A., Johansson, U., & Nilsson, J. (2025) · JMIR Diabetes · doi:10.2196/66117 · Cited by 12
“Research shows an increase in the use of CGM [4], CSII [5], and AID [4] in recent years.”
Shah, V. N., Agesen, R. M., Bardtrum, L., Christiansen, E., SNAITH, J. R., & Greenfield, J. R. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241305647 · Cited by 11
Self-citationSNAITH, J. R., Narongkiatikhun, P., Bjornstad, P., Greenfield, J. R., & Tommerdahl, K. L. (2025) · Diabetes Care · doi:10.2337/dci25-0015 · Cited by 19
Klein, M. P., Aktürk, H. K., Snell‐Bergeon, J. K., & Shah, V. N. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241245680 · Cited by 13
“13,14 This study was approved by the Colorado Multiple Institutional Review Board (COMIRB) under the exempt category.”
Self-citationMerino-Torres, J. F., Ilham, S., Alshannaq, H. A., Pollock, R. F., Ahmed, W., & Norman, G. J. (2024) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s483459 · Cited by 8
“36–38 The annual modeled increase of HbA1c in the SMBG arm after the first year and in the rt-CGM arm after the third year was identical ie , +0.15 units per annum (based on the CDM default clinical table).”
MethodInfluentialSomolinos-Simón, F. J., García-Sáez, G., Tapia, J. A. R., Corcoy, R., & Hernando, M. E. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111803 · Cited by 7
Saeed, Z. I., Aktürk, H. K., Aleppo, G., Kruger, D. F., Levy, C. J., Mader, J. K., Sherr, J. L., & Shah, V. N. (2024) · Clinical Diabetes · doi:10.2337/cd24-0067 · Cited by 8
Self-citationNigi, L., Batzibal, M. S., Cataldo, D., & Dotta, F. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01656-w · Cited by 7
Noninsulin Therapies in Management of Type 1 Diabetes
Saeed, Z. I., Ambalavanan, J., Rayan, M. N., Patadia, P., & Shah, V. N. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.06.027 · Cited by 7
Self-citationElbarbary, N. S., & Ismail, E. A. R. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112042 · Cited by 8
Mathioudakis, N. N., Wolf, R. M., Choudhary, A., Davis, G. M., GALLAGHER, M. P., Gupta, M., Kamboj, M. K., Rioles, N. A., OSPELT, E. L., Thapa, S., et al. (2025) · JMIR Research Protocols · doi:10.2196/71038 · Cited by 4
“Continuous glucose monitors (CGM) and automated insulin delivery (AID) systems have not only led to improved quality of life but also better glycemic outcomes and reduced incidence of hospitalizations for severe hypoglycemia and diabetic ketoacidosis (DKA) [1,2].”
Li, H., Wang, J., Zhang, T., Lou, P., Xu, L., & Ma, L. (2025) · BMC Public Health · doi:10.1186/s12889-025-24674-0 · Cited by 6
Aktürk, H. K. (2024) · Diabetes Care · doi:10.2337/dci24-0002 · Cited by 4
Association Between Time-in-Range and Diabetic Retinopathy: Learnings from DCCT to Recent Times
Shah, V. N., Kanapka, L. G., Beck, R. W., & Kovatchev, B. P. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0169 · Cited by 3
“11 While during DCCT (1983 – 1993), nearly 60% were on multiple daily injections with glucose monitoring solely done with capillary blood tests.”
Self-citationJENDLE, J. H., Ilham, S., Alshannaq, H. A., Matuoka, J. Y., Pollock, R. F., Ahmed, W., & Norman, G. J. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01811-x · Cited by 2
Sawyer, A., Forlenza, G. P., & Wadwa, R. P. (2025) · Expert Review of Medical Devices · doi:10.1080/17434440.2025.2585061 · Cited by 2
“Increasing use of diabetes technology is associated with lower HbA1c and more patients achieving the target HbA1c of 7% [16].”
Early Stages of Automated Insulin Delivery
Zisser, H., Hovorka, R., Basu, A., Battelino, T., Boughton, C. K., Breton, M. D., Buckingham, B. A., Brown, S. A., Cherñavvsky, D. R., Dassau, E., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.18802.hz · Cited by 3
“89,93,96,97,119,120 This disappointing outcome is primarily due to the mismatch between the slow absorption of subcutaneous insulin 121 and rapid absorption of carbohydrate, hindering the ability of the systems to counteract variations in postprandial glucose levels.”
Self-citationAlshannaq, H. A., Simmons, D. S., Matuoka, J. Y., Pollock, R. F., Tucker, M., Ahmed, M. U., & Norman, G. J. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03430-1 · Cited by 3
“Based on longitudinal studies demonstrating glycemic improvements for up to 10 years, this effect was assumed to be sustained for 3 years in the RT-CGM group [23–25].”
Burger, J., & Hess, R. (2025) · Journal of Pharmacy Practice · doi:10.1177/08971900251408940 · Cited by 1
Zaharieva, D. P., KINGMAN, R. S., Lal, R., Nykaza, E., Buckingham, B. A., & Hughes, M. S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70715 · Cited by 1
“Adoption of diabetes technology has increased steadily over the past decade [1–3], and automated insulin delivery (AID) systems represent a fundamental advancement leading to improvements in glycemic outcomes for youth with type 1 diabetes (T1D) [4–6].”
Kietaibl, A.-T., Schütz-Fuhrmann, I., Bozkurt, L., Frühwald, L., Rami-Merhar, B. M., Fröhlich-Reiterer, E. E., Hofer, S. E., Tauschmann, M., Resl, M., Hörtenhuber, T., et al. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02400-x · Cited by 3
Karakus, K. E., Snell‐Bergeon, J. K., Mason, E., & Aktürk, H. K. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241301429 · Cited by 1
Self-citationPsychosocial predictors of short-term glucose among people with diabetes: A narrative review
Horner, F. S., & Helgeson, V. S. (2024) · Journal of Behavioral Medicine · doi:10.1007/s10865-024-00536-9 · Cited by 1
“Although CGMs have been available for years, recent improvements in size, ease of use, and insurance coverage have led to increased usage, particularly among people with T1D (Karakus et al., 2023).”
Early Stages of Automated Insulin Delivery
Zisser, H., Hovorka, R., Basu, A., Battelino, T., Boughton, C. K., Breton, M. D., Buckingham, B. A., Brown, S. A., Cherñavvsky, D. R., Dassau, E., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251335685 · Cited by 2
“89,93,96,97,119,120 This disappointing outcome is primarily due to the mismatch between the slow absorption of sub-cutaneous insulin 121 and rapid absorption of carbohydrate, hindering the ability of the systems to counteract variations in postprandial glucose levels.”
Self-citationKim, J. Y., Ilham, S., Alshannaq, H. A., Pollock, R. F., Field, M., Norman, G. J., Jin, S., & Kim, J. H. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251382570 · Cited by 2
Shah, V. N., Aktürk, H. K., Trahan, A. C., Piquette, N., Wheatcroft, A., Schertz, E. M., CARMELO, K., Müeller, L., WHITE, K. N., Fu, L., et al. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241229074 · Cited by 1
Self-citationLameijer, A. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.1021051970
Alshannaq, H. A., Matuoka, J. Y., Pollock, R. F., Ahmed, W., Lynch, P. M., & Norman, G. J. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.8.752 · Cited by 2
Hypophosphatasia and Type 1 Diabetes: A Pilot Study and Review of Literature
Tariq, Z., Tinsley, J. P., Carpenter, R. D., Snell‐Bergeon, J. K., & Shah, V. N. (2025) · Current Osteoporosis Reports · doi:10.1007/s11914-025-00938-x
Self-citationCourtney, A., Comerford, S., & Owens, L. A. (2026) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-025-04245-3
Zaharieva, D. P. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00406-1
Watada, H., Tanaka, S., Matuoka, J. Y., Alshannaq, H. A., Pollock, R. F., Field, M., & Norman, G. J. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70279
ARMAN, D., Haynes, E. M. K., BRUSSONI, M. J., Gadermann, A., Sideroff, T. C., HEERDEN, L. V., Jun, J., & Voss, C. (2026) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005635
OSPELT, E. L., Wright, T., Indyk, J. A., RIOLES, N., Thapa, S., Beckwitt, A., Ebekozien, O. A., Hopkins, R. L., ERARDI, J., Choudhary, A., et al. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261443333
Hilliard, M. E., Minard, C. G., Carreon, S. A., Levy, W. L., Lyons, S. K., Streisand, R. M., Tang, T. S., McKay, S. V., Devaraj, S., & Anderson, B. J. (2026) · Diabetes Care · doi:10.2337/dc26-0395
Neuroretinal Layer Thinning on OCT Imaging and Hemoglobin A 1 c in Youth With Type 1 Diabetes
Ramanujam, S., Channa, R., Liu, T. Y. A., Brown, E. A., Parimi, N., Kim, Y. C., Bromberger, L. A., Lehmann, H. P., Abràmoff, M. D., & Wolf, R. M. (2026) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2026.1341 · Cited by 1
Nicholas, J. A., Yeap, B. B., CROSS, D. S., Bear, N., & Burkhardt, M. S. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70336
Metadata
- Authors
- Karakus, K. E., Akturk, H. K., Alonso, G. T., Snell-Bergeon, J. K., & Shah, V. N.
- Affiliations
- Koç University (TR)
- 1Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO
- University of Colorado Anschutz (US)
- Corresponding author
- Shah, Viral N.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-07-17
- Volume
- 46
- Issue
- 9
- Pages
- 1646-1651
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4384560404
- Cited by
- 52
- References
- 28
- Citations by year
- 2026: 9 · 2025: 19 · 2024: 24
- FWCI
- 10.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- type 1 diabetes, diabetes technology, continuous glucose monitoring, artificial pancreas, glycemic control, HbA1c, adults, technology adoption trends, glycemic targets
- MeSH terms
- Adolescent, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Blood Glucose Self-Monitoring, Pancreas, Artificial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.